What Is Steady State in Dosing?

Every medicine given repeatedly gradually accumulates in the body. Each dose adds a certain amount of the substance; at the same time, the body continuously metabolizes and eliminates it. Steady state is reached when these two processes balance out: the amount added by each dose matches the amount the body eliminates before the next one.¹

In practice, this means the plasma concentration (the level of the substance in the blood) stops rising systematically and settles into a predictable pattern. It still fluctuates between the trough just before each dose and the peak shortly after it, but this rhythm repeats consistently, dose after dose.

When steady state occurs

The time needed to reach steady state depends exclusively on the biological half-life (t½) of the substance: the time it takes for plasma concentration to fall to half of its starting value. The pharmacological convention is that steady state occurs after roughly four to five half-lives.¹

The dose size and dosing frequency do not change this time. They determine what level steady state settles at, not how quickly it is reached.

→ How half-life works and what follows from it: biological half-life (t½)

An example you may know: Ozempic

Semaglutide (Ozempic, Wegovy) has a half-life of roughly seven days and is administered once weekly.² The dosing interval therefore matches the half-life exactly. This is not just administrative convenience; it creates a specific mathematical consequence.

For a substance where the dosing interval equals the half-life, the rule is exact: the steady-state peak is twice the first peak. After the first injection, concentration rises to a certain level and then falls by half over a week; the second dose raises it to 1.5 times the starting peak. Each following week, the increments get smaller and concentration approaches a fixed ceiling that is exactly twice the first peak.¹ If plasma concentration and pharmacological effect were directly proportional, which is a simplification clinical reality only approximately follows, the steady-state effect would be twice as strong as after the first dose.

This creates a less obvious but important symmetry: the steady-state trough, the lowest level just before the fifth or sixth injection, is exactly equal to the first peak. After stabilization, the minimum level matches the maximum level after the first dose.

What to watch for: Semaglutide concentration rises across the full first four to five weeks, even if the dose is not changed. Someone who tolerates the first injection without problems still needs to account for the fact that the body is moving toward levels twice as high. Nausea or other adverse effects appearing in the third or fourth week on the same dose are not an anomaly; they are the result of plasma concentration still rising toward steady state. That is exactly why titration protocols prescribe four weeks at each dose level: it is the minimum time needed for the level to stabilize enough to judge whether the dose fits.

GLP-1 agonists: same logic, different values

The same principle applies to other medicines in the incretin receptor agonist group, with one difference: each molecule has a different half-life, so the degree of accumulation differs as well.

Tirzepatide (Mounjaro) has a half-life of roughly five days and is also dosed weekly.³ Because its half-life is shorter than the dosing interval, accumulation is lower: the steady-state peak reaches about 1.6 times the first dose, not twice as high as with semaglutide.

Why not every day? A shorter dosing interval would create a more stable plasma level with smaller fluctuations. Liraglutide (Victoza), an older GLP-1 agonist with a half-life of roughly thirteen hours, is administered daily.⁴ The move to semaglutide was a deliberate shift toward weekly dosing: a compromise where patient adherence in clinical practice outweighs slightly smoother pharmacokinetics.

What steady state does not tell you

Steady state describes when concentration stabilizes, not how high it will be or what happens after the first dose. Those questions belong to other concepts:

• How high the level peaks after each dose → Peak plasma concentration (Cmax)
• How quickly the substance leaves the body → biological half-life (t½)